- CITATIONS: 1
|Application ||WB, IHC|
|Calculated MW||68678 Da|
|Other Names||Alpha-fetoprotein, Alpha-1-fetoprotein, Alpha-fetoglobulin, AFP, HPAFP|
|Target/Specificity||A synthetic peptide corresponding to residues near the C-term of human AFP was used as an immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||AFP Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Binds copper, nickel, and fatty acids as well as, and bilirubin less well than, serum albumin. Only a small percentage (less than 2%) of the human AFP shows estrogen-binding properties.|
|Tissue Location||Plasma. Synthesized by the fetal liver and yolk sac|
Provided below are standard protocols that you may find useful for product applications.
Alpha-fetoprotein (AFP) is a serum glycoprotein protein produced in the liver or yolk sac of fetal staged mammals. AFP synthesis is minimal after birth and trace amount is expressed in the adult liver (1). AFP gene expression is regulated by the interactions between steroid hormone receptors and transcriptional factors in separate signal transduction pathways (2). AFP functions as a binding and transporting ligand and cell growth regulator. Elevated expression level of AFP has been implicated in colorectal, ovarian, pancreatic, testicular, and certain liver cancers. High levels of AFP is also seen in some diseases such as hepatitis and colitis. AFP is used as a screening marker for fetal abnormalities in pregnant women such as Down syndrome. Recently, AFP has been introduced as an anti-cancer drugs-ligand carrier, transporting drugs to target tumor cells, increasing anti-tumor efficiency (3).
1. Wang XW, et al. World J Gastroenterol 7:345-351, 2001.
2. Chen H, et al Crit Rev Eukaryot Gene Expr, 7:11-41, 1997.
3. Zheng AI, et al. CJC 22:108-111, 2003.
If you have any additional inquiries please email technical services at email@example.com.